Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities that manufacture or process products for the U.S. market are required to designate a U.S. ...
When evaluating providers for a U.S. Agent under the Modernization of Cosmetics Regulation Act (MoCRA), what key factors and service levels typically influence the overall cost? The requirement for f...
When medical device manufacturers plan their compliance budgets for 2026, forecasting the cost of outsourced services like the Person Responsible for Regulatory Compliance (PRRC) is a critical task. G...
While establishing a precise budget for a Person Responsible for Regulatory Compliance (PRRC) service for 2026 is challenging without specific quotes, manufacturers can forecast costs by understanding...
For a company handling the personal data of EU residents, such as a Software as a Medical Device (SaMD) developer collecting user health information, appointing a GDPR Article 27 representative is a m...
Given the increasing connectivity of medical devices, how should a manufacturer of a Class II device, such as an integrated continuous glucose monitoring system (iCGM) identified under 21 CFR 862.1355...
For non-EU medical device manufacturers preparing for the EU’s Carbon Border Adjustment Mechanism (CBAM), how should they strategically differentiate between the responsibilities of their required Med...
For a non-EU medical device manufacturer preparing for the European market, how should the selection process for an EU Authorized Representative (AR) be structured to ensure full compliance with the E...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign facilities that manufacture or process cosmetic products for the U.S. market face new mandatory compliance obl...
Under the Modernization of Cosmetics Regulation Act (MoCRA), what are the specific responsibilities of a U.S. Agent for a foreign cosmetic establishment, and how has this role changed? With the imple...
Under the EU Medical Device Regulation (MDR), many manufacturers, particularly small to medium-sized enterprises or those based outside the European Union, opt to outsource the function of the Person ...
When planning for 2026, medical device manufacturers seeking to comply with European regulations often budget for a 'Person Responsible for Regulatory Compliance' (PRRC) as a service. However, the cos...
For manufacturers of in vitro diagnostic (IVD) components, what are the critical regulatory factors that distinguish the marketing pathway for an Analyte Specific Reagent (ASR) from the requirements f...
With the ECHA Forum announcing a pilot project focusing on Only Representatives (ORs) and with inspections planned for 2026, how can non-EU manufacturers of medical device components or materials cond...
With the ECHA Forum's announcement of a 2026 pilot project focused on inspecting Only Representatives (ORs), how can a non-EEA manufacturer develop a comprehensive evaluation framework to select a com...
For medical device manufacturers based outside the European Union, selecting an EU Authorized Representative (AR) is a critical step for market access under the Medical Device Regulation (MDR). Beyond...
When selecting an EU Authorized Representative (AR) under the Medical Device Regulation (MDR), what specific criteria should non-EU manufacturers use to evaluate potential partners beyond basic regist...
When non-EU manufacturers budget for compliance with the Medical Device Regulation (MDR), the cost of an EU Authorized Representative (AR) is a significant consideration that extends beyond a simple a...
For foreign cosmetic establishments required to appoint an FDA U.S. Agent under the Modernization of Cosmetics Regulation Act (MoCRA), how can the total cost and value of this service be evaluated bey...
What are the primary factors that determine the annual cost of retaining an FDA U.S. Agent, and how can foreign establishments differentiate between a basic service agreement and a more comprehensive ...